A phase 2 clinical trial of VVN461, a nonsteroidal dual Janus kinase 1/tyrosine kinase 2 immunomodulator, met the primary endpoint of statistical and clinical efficacy vs. vehicle for the treatment of inflammation after cataract surgery.
According to a press release from VivaVision Biotech, 91 patients undergoing routine unilateral cataract extraction in the multicenter, randomized, double-masked, vehicle-controlled study were randomly assigned to receive VVN461 1% (30 patients), VVN461 0.5% (30 patients) or vehicle (31 patients). Patients were treated four times a day for 14 days.
At day 14,